3MSModified Mini-Mental State Examination (dementia screening test)
References in periodicals archive ?
Cognitive function was measured using the 3MS at baseline and at 3, 5, and 8 years, and cytokines IL-6, CRP, and TNF-[alpha] were used as serum markers of inflammation.
The goal of 3MS is to enhance marketing and media management decision-making.
The researchers identified four food groups that were independently associated with better 3MS scores: dairy, vegetables, whole grains, and nuts and beans.
After closer examination of the data, the participants with metabolic syndrome who were in the high-inflammation sub-group averaged a roughly 1 point/year faster decline in 3MS scores, compared with those without metabolic syndrome or those with metabolic syndrome but with a low level of systemic inflammation, Dr.
Another 5% had impaired global cognition based on a 3MS score below 23, but not impaired executive function.
In contrast, women with baseline impairment only on the 3MS had a statistically nonsignificant 1.
High cognitive function was defined as scoring 96 points or greater on the 3MS and 47 points or greater on the DSST.
The adoption of the SafeFrame specifications will be critical for implementation of these 3MS standards.
To launch the competition, 3MS unveiled the second of its own PSA videos, dubbed 'White Wall', which brings to life a metaphor for paying for ads that are never seen.
We are strong supporters of the IAB's 3MS Initiative and we believe our new Viewability tools can assist in that effort.
3MS was founded by the American Association of Advertising Agencies (4A's), the Association of National Advertisers (ANA), and the Interactive Advertising Bureau (IAB), driven by a need across the marketing and advertising industry for clear and standards-based metrics for interactive advertising that are comparable to legacy media and based on the fundamental opportunity for consumers to see online ads.
Though 3MS and Trails B were not the primary outcome measures in the study, they are well-established cognitive measures and, therefore, may suggest other ways to measure change in future Alzheimer's disease clinical trials," Relkin said.